Kanion Pharmaceutical(SH:600557) Ge Long Hui·2025-11-26 12:11Core Viewpoint - Kangyuan Pharmaceutical (600557.SH) is actively responding to the increased demand for its respiratory and infectious disease products, particularly during the flu season, by ramping up production to meet market needs [1] Product Overview - The company's representative products in the respiratory and infectious disease line include: - Re Du Ning Injection: Used for treating symptoms of wind-heat colds and upper respiratory infections, showing significant efficacy in alleviating fever and respiratory symptoms [1] - Jin Zhen Oral Solution: A pediatric traditional Chinese medicine that effectively treats acute bronchitis in children and shows antiviral properties against influenza viruses, enhancing clinical cure rates when combined with Oseltamivir [1] - Xing Bei Cough Granules: Effective for cough relief and lung function improvement in cases of external cold and internal heat [1] - San Han Hua Shi Granules: Used for treating diseases caused by cold and dampness affecting the lungs [1] - Yin Qiao Qing Re Tablets: Treats common colds with wind-heat symptoms, providing multiple therapeutic effects [1] - Wen Yang Jie Du Granules: Aids in improving symptoms related to weakened Yang energy in patients, showing good clinical efficacy [1] Market Demand - The national influenza activity has significantly increased, entering a rapid rise phase, leading to a notable growth in demand for the company's core products in the anti-infection and respiratory sectors during the flu season [1]